ストックスクリーナーアプリを入手
26.20
1.67%
0.43
アフターアワーズ：
26.20
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
Should EMA’s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative? - simplywall.st
RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating - marketscreener.com
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief Talent Officer - GuruFocus
ACADIA Pharmaceuticals Inc. (ACAD) Latest Stock News & Headlines - Yahoo Finance
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer - FinancialContent
ACADAcadia Pharmaceuticals Inc Forecast, Target Price - Finviz
Understanding the Setup: (ACAD) and Scalable Risk - Stock Traders Daily
Acadia Pharma EVP Schneyer sells $60k in stock - Investing.com
Price to earnings forward of ACADIA Pharmaceuticals Inc. – BIVA:ACAD - TradingView
Price to book forward of ACADIA Pharmaceuticals Inc. – LSX:603035 - TradingView
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results - Investing.com
ACAD stock eyes best day in over a year as CHMP recommends approval for rare nerve disorder drug in Europe - MSN
ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now - TMX Newsfile
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds - simplywall.st
ACAD Maintains Buy Rating -- Price Target Raised to $30.00 by B of A Securities - GuruFocus
Why Acadia Pharmaceuticals stock is soaring today - MSN
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $30 to $37 - Moomoo
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating on EU progress - Investing.com
ACADIA Pharmaceuticals Price Target Raised to $35.00/Share From $32.00 by Citigroup - Moomoo
Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
Acadia Pharmaceuticals principal accounting officer sells $297,912 - Investing.com UK
Acadia Pharmaceuticals principal accounting officer sells $297,912 By Investing.com - Investing.com Nigeria
Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa
ACADIA PHARMACEUTICALS (ACAD) officer sells 11,421 shares under 10b5-1 plan - Stock Titan
ACAD stock up as CHMP backs Daybu for EU approval in Rett syndrome - MSN
ACAD Maintained by Canaccord Genuity -- Price Target Raised to $36.00 - GuruFocus
ACAD Maintained by Citigroup -- Price Target Raised to $35 - GuruFocus
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome - The Globe and Mail
EMA reverses its stance on Acadia’s Rett syndrome therapy Daybu - BioWorld News
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus - Seeking Alpha
Acadia Pharmaceuticals (ACAD) Receives Positive CHMP Opinion for DAYBU Approval - GuruFocus
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus (NASDAQ:ACAD) - Seeking Alpha
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Deutsche Bank Raises Price Target on ACADIA Pharmaceuticals to $37 From $32, Keeps Buy Rating - marketscreener.com
Canaccord raises Acadia Pharmaceuticals price target on EU approval By Investing.com - Investing.com Canada
Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus
Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Neuren’s DAYBU® Receives Positive EU Recommendation for Rett Syndrome Treatment - Sharecafe
Why ACADIA Pharmaceuticals (ACAD) Is Up 17.1% After EMA Backs DAYBU For Rett Syndrome - Sahm
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy - Sahm
Acadia Pharmaceuticals (ACAD) Receives Positive Opinion for Dayb - GuruFocus
Acadia rises as EU backs Rett syndrome therapy - MSN
Acadia Pharmaceuticals (ACAD) Shares Surge After EMA Panel Endor - GuruFocus
Form 144 ACADIA PHARMACEUTICALS INC For: 26 June By Investing.com - Investing.com South Africa
Sector Update: Healthcare - Moomoo
Form 144 ACADIA PHARMACEUTICALS INC For: 26 June - Investing.com UK
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits
Biotech Blows Into Breakout Territory On A Surprising Reversal - Investor's Business Daily
[144] ACADIA PHARMACEUTICALS INC SEC Filing - Stock Titan
Acadia Pharmaceuticals (ACAD) Sees Significant Price Surge - GuruFocus
CHMP recommends approval of Acadia’s Rett syndrome treatment in EU By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals stock gets $23 price target from Oppenheimer on CHMP reversal - Investing.com
Why Acadia Pharmaceuticals Stock Is Soaring Today - The Motley Fool
1.18%
2.48%
大文字化:
|
ボリューム (24 時間):